Abstract Objective To study the clinical effect of continuous subcutaneous insulin infusion (CSⅡ) versus multiple daily injection (MDI) on blood glucose control in children with type 1 diabetes mellitus (T1DM). Methods A retrospective analysis was performed on the medical data of 91 children with T1DM who were treated with CSⅡ for more than 1 year and 75 children with T1DM who were treated with MDI. The two groups were compared in terms of glycosylated hemoglobin (HbA1C) and the recurrence of diabetic ketoacidosis (DKA) to evaluate the difference in the efficacy during the 3-year follow-up. A survey was conducted for the children in the CSⅡ group and their family members to investigate the degree of satisfaction with insulin pump. Results There was no significant difference in age, sex, and course of diabetes between the CSⅡ and MDI groups at disease onset and in the first year, the second year, and the third year of follow-up (P > 0.05). There was no significant difference in the HbA1C level between the two groups at disease onset (P > 0.05), but in the first year of follow-up, the CSⅡ group had a significantly lower HbA1C level than the MDI group (P=0.04). There was no significant difference in the HbA1C level between the two groups in the second year and the third year of follow-up (P > 0.05). The CSⅡ group had a higher proportion of children with HbA1C<7.5% than the MDI group in the first year, the second year, and the third year of follow-up (P > 0.05). Within the 3 years of follow-up, 2 children in the CSⅡ group and 8 in the MDI group experienced the recurrence of DKA. In the third year of follow-up, there was no significant difference in blood pressure and blood lipids between the CSⅡ and MDI groups (P > 0.05). Most children and their family members (87%) were satisfied with CSⅡ treatment. Conclusions Children with T1DM treated with CSⅡ have a better control of blood glucose than those treated with MDI, and children and their family members are satisfied with CSⅡ treatment. Therefore, it holds promise for clinical application.
YANG Hong-Xiu,LENG Xue-Fei,HU Si-Cui et al. Long-term follow-up of efficacy of insulin pump in the treatment of children with type 1 diabetes mellitus[J]. CJCP, 2021, 23(2): 116-120.
YANG Hong-Xiu,LENG Xue-Fei,HU Si-Cui et al. Long-term follow-up of efficacy of insulin pump in the treatment of children with type 1 diabetes mellitus[J]. CJCP, 2021, 23(2): 116-120.
Carracher AM, Marathe PH, Close KL. International diabetes federation 2017[J]. J Diabetes, 2018, 10(5):353-356.
[2]
Weng JP, Zhou ZG, Guo LX, et al. Incidence of type 1 diabetes in China, 2010-13:population based study[J]. BMJ, 2018, 360:j5295.
[3]
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes[J]. Engl J Med, 2005, 353(25):2643-2653.
[4]
Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus:Diabetes Control and Complications Trial[J]. J Pediatr, 1994, 125(2):177-188.
World Health Organization. Classification of diabetes mellitus[EB/OL]. (2019-04-21)[2020-02-06]. https://www.who.int/publications/i/item/classification-of-diabetes-mellitus.
[7]
Polonsky WH, Hessler D, Ruedy KJ, et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes:further findings from the DIAMOND randomized clinical trial[J]. Diabetes Care, 2017, 40(6):736-741.
[8]
Rubin RR, Peyrot M, STAR 3 Study Group. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3(STAR 3) trial[J]. Diabetes Technol Ther, 2012, 14(2):143-151.
[9]
Sherr JL, Hermann JM, Campbell F, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control:comparison of results from three large, transatlantic paediatric registries[J]. Diabetologia, 2016, 59(1):87-91.
[10]
Acerini C, Craig ME, de Beaufort C, et al. Introduction to ISPAD clinical practice consensus guidelines 2014 compendium[J]. Pediatr Diabetes, 2014, 15(S20):1-3.
[11]
Johnson SR, Cooper MN, Jones TW, et al. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study[J]. Diabetologia, 2013, 56(11):2392-2400.
[12]
Korkmaz Ö, Demir G, Çetin H, et al. Effectiveness of continuous subcutaneous insulin infusion pump therapy during five years of treatment on metabolic control in children and adolescents with type 1 diabetes mellitus[J]. J Clin Res Pediatr Endocrinol, 2018, 10(2):147-152.
[13]
Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes:meta-analysis of randomised controlled trials[J]. BMJ, 2002, 324(7339):705.
[14]
Szypowska A, Schwandt A, Svensson J, et al. Insulin pump therapy in children with type 1 diabetes:analysis of data from the SWEET registry[J]. Pediatr Diabetes, 2016, 17(S23):38-45.
[15]
Karges B, Schwandt A, Heidtmann B, et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes[J]. JAMA, 2017, 318(14):1358-1366.
[16]
Danne T, Kordonouri O. Current challenges in children with type 1 diabetes[J]. Pediatr Diabetes, 2007, 8(S6):3-5.
[17]
Mavinkurve M, Quinn A, O'gorman CS. Continuous subcutaneous insulin infusion therapy for type 1 diabetes mellitus in children[J]. Ir J Med Sci, 2016, 185(2):335-340.
